Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

Zeria Pharmaceutical

Status and phase: Completed; Phase 2; Phase 1

Conditions: Pancreatic Cancer

Treatments: Drug: Z-360

Study type: Interventional

Funder types: Industry

Identifiers

NCT00288925

01010106E

Details and patient eligibility

About

To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with unresectable locally advanced or metastatic pancreatic cancer
• KPS > 70%
• Life expectancy of at least 3 months

Exclusion criteria

• received previous chemotherapy for the current indication
• received previous radiotherapy for the current indication
• Currently receiving chemotherapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind